Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab with Docetaxel and Capecitabine in Neoadjuvant Breast Cancer
NCT02005549Phase 2
Key facts
- Status
- Completed
- Start
- Feb 2006
- Primary completion
- Apr 2008
- Countries
- 1
- Sponsor
- Roche
- Modality
- Monoclonal Antibodies
- Drugs
- bevacizumab
- Conditions
- breast cancer
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in breast cancer, sponsored by Roche. Primary endpoint: Pathological Complete Response. Started Feb 2006; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Neoadjuvant Therapy
Bevacizumab + Docetaxel + Capecitabine
03
Who it enrols
Female patients aged 18-70 with histologically-proven invasive breast cancer (HER2-negative based on related publications), no distant disease, and no prior systemic therapy.
04
Endpoints
Primary
Pathological Complete Response
Secondary
Clinical Complete or Partial Response
Rate of Breast-Conserving Surgery
Beyond the preview
Go deeper on NCT02005549.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02005549.